Peptide YY

Peptide YY (PYY), also known as peptide tyrosine tyrosine for its characteristic tyrosine amino acids at both ends of the molecule, is a 36-amino acid peptide hormone that plays a fundamental role in appetite regulation and energy homeostasis. Discovered in 1982 by Tatemoto and colleagues, PYY is produced primarily by specialized enteroendocrine L cells located in the mucosa of the ileum and colon, with smaller amounts found throughout the gastrointestinal tract.

PYY belongs to the pancreatic polypeptide family, sharing structural homology with neuropeptide Y (NPY) and pancreatic polypeptide (PP). This family is characterized by the PP-fold motif—a three-dimensional structure that provides stability against enzymatic degradation. The PP-fold is formed through specific amino acid residues including Pro2, Pro5, Pro8, Gly9, Tyr20, and Tyr27, creating a hydrophobic pocket that protects the peptide's biological activity.

The primary circulating form of PYY is PYY3-36, a 34-amino acid fragment created when the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the first two amino acids from the full-length PYY1-36. This cleavage dramatically changes the peptide's receptor selectivity—while PYY1-36 binds to multiple Y receptors (Y1, Y2, Y5), PYY3-36 has high selectivity for the Y2 receptor, which mediates the majority of PYY's appetite-suppressing effects.

PYY is released in proportion to caloric intake, with levels rising within 15 minutes of eating and remaining elevated for several hours. The magnitude of PYY release depends on the macronutrient composition of the meal, with protein being the most potent stimulator, followed by fat and then carbohydrates. This nutrient-dependent release pattern makes PYY a key player in communicating the body's fed state to the central nervous system.

Peptide YY exerts its effects through a sophisticated signaling cascade that begins in the gut and extends to the central nervous system. Understanding these mechanisms reveals why PYY is considered one of the most important satiety signals in human physiology.

Y2 Receptor Activation

The primary mechanism by which PYY3-36 suppresses appetite involves the Y2 receptor (Y2R), a G protein-coupled receptor expressed in several brain regions, particularly the arcuate nucleus of the hypothalamus. When PYY3-36 binds to Y2R, it inhibits the activity of NPY/AgRP neurons—the primary hunger-promoting neurons in the brain. This inhibition removes the tonic stimulation of appetite, leading to reduced food-seeking behavior and earlier termination of meals.

Interaction with Other Appetite Hormones

PYY doesn't work in isolation—it operates within a complex network of appetite-regulating hormones. Research has demonstrated that PYY3-36 and GLP-1 have additive effects on food intake reduction. Both hormones are released from the same L cells and share similar release patterns following meals. This co-release creates a coordinated satiety response that's more powerful than either hormone alone.

PYY also interacts with ghrelin, often called the "hunger hormone." While ghrelin levels rise before meals to stimulate appetite, PYY rises after eating to suppress it. This reciprocal relationship creates a push-pull dynamic that regulates the timing and size of meals. Studies show that PYY administration can suppress ghrelin-induced hunger, overriding the hunger signal even when ghrelin levels are elevated.

Effects on Gastrointestinal Function

Beyond appetite suppression, PYY exerts significant effects on gastrointestinal physiology. It inhibits gastric motility (the "ileal brake" reflex), slowing the movement of food through the stomach. This delay serves multiple purposes: it extends the period of satiety, allows more thorough digestion, and optimizes nutrient absorption in the small intestine.

PYY also suppresses pancreatic exocrine secretion—the release of digestive enzymes—and promotes water and electrolyte absorption in the colon. These functions help coordinate the entire digestive process, ensuring that the GI tract operates efficiently after a meal.

The research on Peptide YY spans four decades, with significant advances in understanding its role in obesity, bariatric surgery outcomes, and potential therapeutic applications. Here's what the scientific literature reveals about this important satiety hormone.

PYY and Obesity: The Deficiency Hypothesis

A landmark 2002 study published in Endocrinology demonstrated that obese individuals have a blunted PYY response to meals compared to lean individuals. While lean subjects showed robust increases in circulating PYY after eating, obese subjects had significantly lower postprandial PYY levels. Importantly, this wasn't due to receptor insensitivity—when given exogenous PYY, obese individuals responded normally with reduced appetite.

This finding suggested that insufficient PYY secretion, rather than PYY resistance, may contribute to obesity. The implications are significant: unlike leptin, where obesity leads to resistance, PYY represents a potential therapeutic target where simply increasing levels could restore normal satiety signaling.

Clinical Evidence for Appetite Suppression

The most compelling clinical evidence came from a 2003 New England Journal of Medicine study where researchers infused PYY3-36 into both lean and obese subjects. The results were striking: PYY infusion reduced caloric intake at a buffet meal by approximately 30% in both groups. This effect lasted well beyond the infusion period, suggesting that elevated PYY creates sustained appetite suppression.

Bariatric Surgery and PYY

Some of the most clinically relevant PYY research involves bariatric surgery. Multiple studies have documented dramatically elevated PYY levels following Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy. A 2013 study in the Journal of Clinical Endocrinology and Metabolism showed that these surgeries not only increase PYY but that this increase correlates with improved diabetes outcomes and sustained weight loss.

The mechanism appears to be anatomical: by rerouting food to bypass much of the stomach and upper small intestine, nutrients reach the L cell-rich lower intestine more rapidly, triggering enhanced PYY release. This "hindgut hypothesis" explains why surgical patients often report profound changes in appetite and food preferences that exceed what caloric restriction alone would predict.

Synergy with GLP-1

Research published in Endocrinology (2005) demonstrated that PYY3-36 and GLP-1-7-36 amide (the active form of GLP-1) have additive effects when administered together. Mice receiving both peptides ate significantly less than those receiving either peptide alone. This finding has important implications for combination therapy development and helps explain why bariatric surgery—which increases both hormones—produces such profound appetite effects.

Dietary Influences on PYY

Nutritional studies have clarified how different macronutrients affect PYY release. Protein consistently produces the greatest PYY response, followed by fat and then carbohydrates. A study examining the effects of protein intake found that high-protein diets produced sustained elevations in PYY that correlated with reduced hunger and increased satiety ratings. This may partially explain the success of high-protein diets for weight management.

Dietary fiber also influences PYY levels by speeding intestinal transit and delivering nutrients to the lower gut more quickly. Whole grains, vegetables, and fruits that reach the ileum intact can trigger L cell activation and PYY release, supporting the satiety benefits traditionally associated with high-fiber diets.

Ongoing Research Directions

Current research focuses on developing practical PYY-based therapies. Challenges include the peptide's short half-life and the need for injection. Approaches under investigation include:

• Long-acting PYY analogs with extended half-lives
• Combination therapies pairing PYY with GLP-1 agonists
• Nasal and oral delivery systems for improved practicality
• Gene therapy approaches to enhance endogenous PYY production
• Small molecule Y2 receptor agonists as oral alternatives

Peptide YY remains primarily a research tool rather than an approved therapeutic agent. The following information reflects dosing parameters used in clinical research studies and is presented for educational purposes only. Human clinical use should only occur under medical supervision in appropriate research settings.

Research Study Protocols

In the landmark clinical studies demonstrating PYY's appetite-suppressing effects, researchers typically used intravenous infusion protocols. The 2003 New England Journal of Medicine study employed PYY3-36 at 0.8 pmol/kg/min for 90 minutes, designed to achieve circulating levels approximately 50% above normal postprandial concentrations.

Form and Stability

PYY is typically supplied as a lyophilized (freeze-dried) powder requiring reconstitution before use. For research applications:

• Reconstitution: Sterile water, saline, or appropriate buffer
• Lyophilized storage: -20°C to -80°C for long-term stability
• Reconstituted storage: 2-8°C, typically used within 7-14 days
• Avoid: Repeated freeze-thaw cycles which degrade the peptide

Pharmacokinetic Considerations

PYY has a relatively short plasma half-life of approximately 10-30 minutes, which presents challenges for therapeutic development. The active form PYY3-36 has a slightly longer half-life than full-length PYY1-36 due to its resistance to DPP-4 cleavage (it's already been processed by DPP-4).

The short half-life means that sustained appetite suppression requires either continuous infusion or development of modified analogs with extended duration of action. Research into long-acting PYY formulations is ongoing, including PEGylated versions and fusion proteins that extend circulating time.

Future Therapeutic Approaches

Given the impracticality of continuous IV infusion for weight management, researchers are exploring alternative delivery methods:

Peptide YY has demonstrated a favorable safety profile in clinical research, reflecting its nature as an endogenous hormone that the body produces naturally. However, as with any bioactive compound, understanding potential effects and considerations is essential.

Observed Effects in Clinical Studies

In the controlled clinical studies conducted with PYY3-36 infusion, most subjects tolerated the peptide well. Reported effects were generally mild and consistent with the peptide's known physiological actions:

• Nausea: Some subjects reported mild nausea, particularly at higher doses. This is consistent with PYY's effect on gastric motility and is similar to effects seen with GLP-1 agonists.
• Reduced appetite: Obviously expected, but the strength of appetite suppression was notable and persisted beyond the infusion period.
• Gastrointestinal effects: Slowed gastric emptying can cause feelings of fullness or mild digestive discomfort.

Theoretical Considerations

Based on PYY's physiological roles, several theoretical considerations merit attention:

Blood Pressure Effects: PYY has been shown to affect vascular function in some studies. Y2 receptors are found on blood vessels, and PYY may influence blood pressure under certain conditions. Clinical significance in therapeutic use remains to be established.

Gastrointestinal Motility: PYY's slowing of gastric emptying, while beneficial for satiety, could theoretically exacerbate conditions involving delayed gastric emptying (gastroparesis). Individuals with existing GI motility disorders should be monitored carefully.

Pancreatic Effects: PYY inhibits pancreatic exocrine secretion. While this is a normal physiological response to feeding, the implications of supraphysiological or prolonged PYY elevation on pancreatic function are not fully characterized.

Comparison to GLP-1 Agonists

The side effect profile of PYY appears similar to but potentially milder than approved GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy). Both can cause nausea and slowed gastric emptying. Whether combination therapy with both hormones would increase or attenuate side effects is an active area of research.

What Remains Unknown

Important gaps in safety knowledge include:

• Long-term safety of sustained elevated PYY levels
• Effects during pregnancy and lactation
• Interactions with other medications, particularly those affecting GI motility or appetite
• Safety in individuals with eating disorders or history of severe caloric restriction
• Effects in pediatric populations